| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Purchases of marketable securities | 89,437 | 71,100 |
| Net cash provided by investing activities | 94,852 | 47,375 |
| Proceeds from issuance of common stock upon exercise of stock options and purchase of shares under espp | 3,124 | 583 |
| Net cash provided by financing activities | 3,124 | 583 |
| Net change in cash, cash equivalents and restricted cash | -11,192 | -30,258 |
| Cash and cash equivalents at beginning of period | 72,097 | - |
| Cash and cash equivalents at end of period | 60,905 | - |
Tango Therapeutics, Inc. (TNGX)
Tango Therapeutics, Inc. (TNGX)